HD-410

HD-410 is a humanized monoclonal antibody currently in preclinical development by the Swedish biotechnology company Diaprost for the treatment of prostate cancer. It is part of Diaprost's "Next Generation" pipeline of antibody-based therapeutics designed for theranostic applications. While the company's more advanced candidates, such as h5A10 and h11B6, target prostate-specific antigen (PSA) and human kallikrein 2 (hK2) respectively, the specific biological target for HD-410 remains proprietary and undisclosed. The asset is intended to serve as a vehicle for targeted radioimmunotherapy or as a diagnostic imaging agent (PET/CT) by being conjugated with radioisotopes, specifically targeting antigens that are overexpressed on the surface of prostate cancer cells.